J. Steinsapir et al., Type 2 lodothyronine deiodinase in rat pituitary tumor cells is inactivated in proteasomes, J CLIN INV, 102(11), 1998, pp. 1895-1899
The goal of these studies was to define the rate-limiting steps in the inac
tivation of type 2 iodothyronine deiodinase (D2). We examined the effects o
f ATP depletion, a lysosomal protease inhibitor, and an inhibitor of actin
polymerization on D2 activity in the presence or absence of cycloheximide o
r 3,3',5'-triiodothyronine (reverse T3, rT3) in rat pituitary tumor cells (
GH4C1). We also analyzed the effects of the proteasomal proteolysis inhibit
or carbobenzoxyL-leucyl-L-leucyl-L-leucinal (MG132). The half-life of D2 ac
tivity in hypothyroid cells was 47 min after cycloheximide and 60 min with
rT3 (3 nM). rT3 and cycloheximide were additive, reducing D2 half-life to 2
0 min. D2 degradation was partially inhibited by ATP depletion, but not by
cytochalasin B or chloroquine. Incubation with MG132 alone increased D2 act
ivity by 30-40% for several hours, and completely blocked the cycloheximide
- or rT3-induced decrease in D2 activity. These results suggest that D2 is
inactivated by proteasomal uptake and that substrate reduces D2 activity by
accelerating degradation through this pathway. This is the first demonstra
tion of a critical role for proteasomes in the post-translational regulatio
n of D2 activity.